Alosetron

Quick links to important sections

Alosetron

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alosetron

Quick Facts

Property Description
Active Ingredient Alosetron hydrochloride
Form Oral tablet (film-coated)
Pharmacological Class Serotonin 5-HT3 receptor antagonist
General Purpose Modulates overactive gut signaling
Origin Synthetic compound

Defining Alosetron: Identity and Pharmacological Class

Alosetron is a prescription-only synthetic medication whose active chemical entity is Alosetron hydrochloride. Pharmacologically, it is classified as a highly selective Serotonin 5-HT3 receptor antagonist. This compound functions by physically blocking specific 5-HT3 receptors, which are key components of the enteric nervous system, the extensive network of nerves controlling the digestive tract. The compound possesses high affinity for these specific receptors.

Composition, Form, and General Therapeutic Role

The medication is formulated for systemic use and supplied as an oral tablet, typically film-coated, ensuring that the single active ingredient, Alosetron hydrochloride, is accurately delivered for absorption via the digestive system. The action of the receptor blockade is designed to stabilize and regulate colonic activity for managing severe forms of digestive distress. This action is intended to help normalize the speed and function of the colon by addressing underlying gut hyper-motility.

Key Distinctions and Targeted Action

The unique distinction of Alosetron lies in its potent and selective action on neuroenteric signaling. This drug is notable for its development primarily to address conditions characterized by chronic, severe diarrhea and associated abdominal discomfort, representing a highly targeted pharmaceutical approach. By interrupting the nerve signals that transmit excessive acceleration and discomfort, the drug offers a neurologically targeted solution. This specific inhibitory action on the 5-HT3 receptor pathways addresses underlying disordered communication, providing a method for establishing a more regulated state of motility.

Regulatory References

  1. Alosetron MedlinePlus Drug Information

What side effects are possible with Alosetron?

Possible Side Effects and Safety Information

The safety profile of Alosetron is specifically characterized by the risk of serious gastrointestinal adverse reactions, as documented in official regulatory labeling. These serious risks, which have been reported with both initial use and long-term exposure, include Ischemic Colitis and Severe Constipation leading to complications such as intestinal obstruction, impaction, or paralytic ileus. The incidence of these serious events is formally classified as uncommon or rare in clinical trial data.


Adverse Reactions by Classification

The most frequently reported adverse reaction is Constipation, which is classified as Common in regulatory documents and represents the primary non-serious side effect. Other common adverse reactions reported across organ classes include Abdominal discomfort and pain, Nausea, and Headache. The adverse effects are primarily grouped under Gastrointestinal Disorders in System-Organ Class (SOC) reporting.


Safety Restrictions and Contraindications

Official labeling defines specific patient safety restrictions. The medicine is contraindicated (prohibited for use) in individuals with a history of chronic or severe constipation, intestinal obstruction, or a previous history of Ischemic Colitis. Furthermore, use is prohibited in patients with severe hepatic impairment. Certain populations, such as older adults (65 years and over), are noted in regulatory documents as having an increased risk of serious complications stemming from constipation. This stringent set of restrictions structures the medicine's overall safety profile, limiting its use to a specific patient population.

Overdose and Emergency Response

The official regulatory guidance for Alosetron defines the need for emergency help based on the occurrence of serious gastrointestinal events rather than a typical acute high-dose overdose syndrome. These severe events mandate immediate medical attention.


Documented Emergency Manifestations

Signs requiring urgent action include severe complications of constipation, such as obstruction, ileus, impaction, toxic megacolon, and secondary bowel ischemia. Urgent attention is also required for symptoms of Ischemic Colitis, including rectal bleeding, bloody diarrhea, or new or worsening abdominal pain. These life-threatening conditions have been associated with rare outcomes, including bowel perforation and death (rarely reported), and may necessitate hospitalization or surgery.


Required Emergency Actions

Regulatory labeling mandates the immediate discontinuation of Alosetron if either constipation or any signs of Ischemic Colitis occur. Patients must immediately report these symptoms to a healthcare provider, and prompt evaluation is required for suspected Ischemic Colitis. No specific antidote is officially documented. Elderly and debilitated patients have an increased risk for serious constipation complications, and the drug is contraindicated in patients with severe hepatic impairment due to heightened risk of serious adverse reactions.

Therapeutic Uses of Alosetron

What Alosetron Treats: Main Uses and Benefits

Alosetron is considered relevant for adult female patients with severe diarrhea-predominant Irritable Bowel Syndrome ( IBS-D), a chronic condition where symptoms have not found adequate relief from other common symptomatic management strategies. The medication is used for managing symptoms that create noticeable physiological strain and heightened symptoms of IBS-D. This includes addressing symptom clusters such as frequent, loose stools, severe abdominal cramping, and bowel urgency; these manifestations generally interfere with daily functioning.

Its use is indicated in clinical settings that involve chronic, functionally limiting symptoms. This supportive relief generally contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort.

Quick Fact: Relief for Severe Diarrhea-Predominant IBS

  • Indications Focus: Chronic symptoms lasting six months or longer, which have not found adequate relief from other symptomatic management strategies.
  • Symptom Benefit: Assists with easing increased stool frequency and associated abdominal discomfort.
  • Patient Benefit: Supports maintaining functional stability and helps patients cope more steadily with symptom fluctuations.

Eligibility and Restrictions for Use

Who Can and Cannot Use Alosetron?

Alosetron use is restricted by regulatory authorities based on gender, age, medical history, and specific conditions. The medicine is indicated only for adult women (18 years and older) with severe diarrhea-predominant Irritable Bowel Syndrome (IBS-D) that has not adequately responded to conventional therapies.


Who Must Not Use Alosetron (Contraindications)

Use is absolutely contraindicated in patients with a history of specific gastrointestinal diseases, including ischemic colitis, current or chronic severe constipation, intestinal obstruction, stricture, adhesions, perforation, Crohn's disease, ulcerative colitis, or diverticulitis. It is also prohibited for patients with severe hepatic impairment (severe liver dysfunction) and for patients currently taking fluvoxamine.


Population-Specific Limitations

Population Regulatory Status
Pediatric Patients (under 18) Use is not recommended; safety and effectiveness are not established.
Male Patients Efficacy has not been confirmed.
Mild/Moderate Hepatic Impairment Use requires caution.
Pregnancy Use is permitted only if clearly needed.
Breastfeeding Caution is advised due to a lack of data on presence in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Alosetron's official interaction profile is structured around drugs that affect its clearance and those that share a pharmacodynamic risk of gastrointestinal complications. Co-administration with the strong CYP1A2 inhibitor Fluvoxamine is contraindicated because regulatory data show it increases Alosetron plasma exposure (AUC) approximately six-fold. Use with other strong CYP1A2 inhibitors should also be avoided.

Pharmacokinetic and Pharmacodynamic Interactions

Category Example or Restriction Official Regulatory Finding
CYP3A4 Inhibition General class restriction Co-administration requires caution due to increased Alosetron exposure.
GI Motility Agents Medicines that decrease motility Increased risk of serious complications of constipation due to additive effects.

Co-administration with Cimetidine is documented to cause a 40% increase in Alosetron exposure. Concerning drug-food interaction, absorption is decreased by approximately 25% when taken with food; however, administration is permitted without regard to meals.

Population-Specific Interaction Constraints

Severe Hepatic Impairment is listed as a contraindication because compromised liver function can compromise clearance, leading to increased systemic exposure. Use in patients with mild or moderate hepatic impairment also requires caution.

Mechanism of Action

How Alosetron Works: Mechanism of Action


Serotonin Receptor Antagonism and Gut Quieting

Alosetron functions as a highly selective antagonist of the Serotonin 5- HT3 receptor (5- HT3R), a ligand-gated ion channel found primarily on enteric sensory nerve terminals. By blocking this receptor, the drug inhibits the neuronal depolarization normally triggered by endogenous serotonin, thereby suppressing overactive signaling. This molecular action directly contributes to the physiological slowing of whole gut transit time and alters water and electrolyte transport dynamics in the colon.


Modulation of Visceral Sensation

The blockade of 5- HT3 receptors on afferent (sensory) neurons modifies the transmission of signals from the gut to the central nervous system. This mechanistic adjustment leads to an elevation of the visceral sensory threshold, meaning the gut requires greater internal activity or distension before afferent signals are initiated. This dampening of the nociception pathway affects the physiological reactivity of the gastrointestinal system.


Mechanistic Constraints

The core mechanism of reducing gut motility is dose-dependent and can result in significant slowing of gut transit, which is recognized as an inherent constraint of this specific receptor antagonism. Furthermore, the magnitude of the physiological effect shows variation, suggesting underlying gender-specific dynamics in the responsiveness of the enteric signaling pathway.

Dosage and Administration Information

Alosetron is administered exclusively via the oral route as a tablet, available in 0.5 mg and 1 mg strengths. The usage protocol includes a titration schedule, beginning with an initial dosage of 0.5 mg taken twice a day. This starting frequency and dose aim to establish initial tolerability.

The treatment plan involves a review after four weeks. If the starting dosage is well tolerated but does not provide adequate control, the dosage may be adjusted upward to a maximum of 1 mg twice a day. Conversely, if constipation occurs at the initial dose, the medication must be temporarily stopped until symptoms resolve, after which it may be reinitiated at a lower frequency of 0.5 mg once a day. If constipation recurs at this lower dose, the drug must be permanently discontinued.

Crucially, the treatment course is subject to specific time limits. If adequate symptom control is not achieved after four weeks at the maximum approved dose of 1 mg twice a day, the drug must be discontinued permanently. Regarding timing, the tablet may be taken with or without food. If a dose is missed, it is skipped and the regular schedule is resumed without taking a double quantity.

Official use is restricted to adult patients, and its use is not established in children. Caution is warranted in older adults and patients with mild or moderate hepatic impairment; use is contraindicated in severe hepatic impairment. Furthermore, prescribing is restricted to physicians enrolled in the drug's specific risk management program.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Alosetron

Evidence for Use in Severe Diarrhea-Dominant IBS (IBS-D)

The research for Alosetron was studied for severe Diarrhea-Dominant Irritable Bowel Syndrome (IBS-D), a condition characterized by fluctuating or episodic manifestations, including symptoms like abdominal discomfort and frequent bowel movements. The primary research base includes short-term Randomized Controlled Trials (RCTs). These studies compared the outcomes of patients receiving Alosetron to those receiving a placebo, or inactive substance. This type of controlled setting was observed in research exploring how symptoms change over time and how patients reported their experiences over a defined period. Research describes findings that were collected during these periods of heightened symptom activity. The evidence base also includes systematic reviews that combine and analyze data from multiple short-term trials to contribute to the broader evidence landscape.

What Research Outcomes Were Measured

The clinical studies was evaluated in studies that examined outcomes reflecting daily functioning or activity level and those related to physical discomfort. The main outcomes studied were composite endpoints: measurements of abdominal pain or discomfort, alongside measurements of bowel function, such as stool consistency and frequency. Additionally, studies monitored patient-reported quality of life measures, which are outcomes related to systemic or functional imbalance. Findings help contextualize how patients reported their experience of symptoms over the trial periods.

Long-Term Studies and Follow-Up

Follow-up durations for controlled, randomized research were limited to several months. This research explores short-term symptom changes but evidence is limited regarding how outcomes persist over years. To address this, data are still emerging from long-term observational settings that are part of post-marketing surveillance programs. This non-randomized evidence, which was observed in some studies, contributes to understanding symptom patterns over longer intervals but does not determine whether an individual will respond similarly after several years of use.

Evidence in Special Populations

Studies explored Alosetron in a very specific patient demographic. The core evidence and findings apply only to the populations studied, which were overwhelmingly adult female patients with severe IBS-D. Consequently, data for certain groups remain insufficient. For instance, comparative evidence is lacking for male patients with IBS-D, and there is limited information on how the research findings relate to patients with less severe forms of the condition.

What Is Still Uncertain About Alosetron Research

Several limitations and gaps exist. One key limitation is that long-term effects are not fully established by controlled trials. While observational research data show patterns related to long-term use, the certainty remains lower compared to controlled studies. Furthermore, the overall patterns observed in the trials was observed against the pattern of high placebo response common in research settings. Evidence quality varies across studies, and the applicability of the findings to the general IBS population is restricted due to the specific criteria for patient selection in the original research.

Frequently Asked Questions (FAQ)

Common questions about Alosetron (FAQ)


Q: What is the difference between Alosetron and over-the-counter IBS medicines?

Alosetron is a prescription-only medication that belongs to a specific class of drugs called Serotonin 5-HT3 receptor antagonists. This mechanism targets and modulates nervous system signals in the gut to affect bowel function, according to regulatory documents. Official product information notes that over-the-counter IBS medicines generally use different mechanisms, such as bulk-forming agents or basic anti-diarrheal ingredients.


Q: What are the most common side effects people report online for Alosetron?

Regulatory documents indicate that the most common side effect reported in clinical studies is constipation, which is often the primary reason treatment may need to be stopped. Other common adverse events reported include abdominal discomfort and pain and nausea.


Q: What safety monitoring is usually recommended when taking Alosetron?

Prescribing of this medicine is restricted to physicians who are enrolled in a specific, mandatory Prescribing Program designed to manage its risks. While kidney impairment does not significantly affect elimination, caution is noted because the effects of end-stage kidney disease and the resulting accumulation of the drug’s byproducts have not been assessed.


Q: What is the likelihood of serious side effects with Alosetron?

The serious risks of ischemic colitis (a serious intestinal inflammation) and complications arising from severe constipation are classified as uncommon or rare events in clinical trial data. Official records report the incidence of serious complications of constipation at approximately one per 1,000 patients in women taking the drug or placebo.


Q: Is Alosetron the only medicine of its kind?

Alosetron is officially classified as a highly selective Serotonin 5-HT3 receptor antagonist and is the only medicine of its type that is specifically approved for the treatment of severe diarrhea-predominant Irritable Bowel Syndrome (IBS-D) in women. The regulatory label describes only its unique pharmacological classification.


Q: What should I do if I notice new or unusual abdominal pain while on Alosetron?

Regulatory patient guidance advises that if new or worsening abdominal pain, bloody diarrhea, or blood in the stool is experienced, treatment should be stopped immediately and a healthcare provider contacted right away. These symptoms may signal a serious condition, such as ischemic colitis.


Q: Is there a maximum time someone can stay on Alosetron?

Clinical trials for determining the effectiveness of the medicine were generally short-term. The regulatory label states that the chance of experiencing ischemic colitis is not known when taking Alosetron for more than 6 months. The decision regarding use beyond the initial assessment period is a determination made by a healthcare provider.


Q: Is it necessary to inform a doctor about all other drugs when starting Alosetron?

Official guidance advises patients to tell their healthcare provider about all health conditions and every medicine they are using. This includes all prescription and over-the-counter (OTC) medicines, vitamins, herbal products, and other supplements to allow for the assessment of potential interactions or complications.


Q: What type of doctor usually prescribes Alosetron?

Alosetron is restricted to being prescribed only by physicians who are enrolled in a specific Prescribing Program. This restriction is required for regulatory compliance due to the serious risks associated with the medicine.


Q: How quickly does Alosetron start to work after the first dose?

Clinical trial data indicated that a statistically significant number of women reported relief of their abdominal pain and discomfort within 1 week of beginning Alosetron therapy. Official prescribing information indicates that a full assessment of whether the drug is providing adequate control is typically conducted after four weeks of use.


Q: Are there any common supplements that should not be taken with Alosetron?

Official documents warn about potential problems when combining Alosetron with certain prescription medicines, such as those that inhibit specific liver enzymes or medicines that decrease bowel motility. Patients are advised to discuss all herbal products and supplements with a healthcare provider before use, as potential interactions should be assessed individually.


Q: Does Alosetron interact with common pain relievers like ibuprofen?

Regulatory information specifies interaction risks related to drugs that influence liver enzyme activity (CYP1A2, CYP3A4). The safety of combining Alosetron with all common over-the-counter pain relievers has not been individually studied. Consultation with a healthcare provider is noted as necessary regarding the use of any specific pain reliever.


Q: Can Alosetron make you feel tired or dizzy?

While tiredness and dizziness are not listed among the most common side effects, adverse event reports from clinical trials and postmarketing experience have included less common reports of fatigue, malaise (general feeling of discomfort), and dizziness or lightheadedness.


Q: Is Alosetron available as a generic drug?

Yes, regulatory databases confirm that Alosetron hydrochloride is listed as available under an Abbreviated New Drug Application (ANDA). This designation indicates that a generic form of the medication is authorized.


Q: Is Alosetron known to cause stomach ulcers or bleeding?

Alosetron is not known to specifically cause stomach ulcers. However, the serious complication of ischemic colitis is associated with severe symptoms, including the potential for rectal bleeding or bloody diarrhea.


Q: Does Alosetron have an effect on mood or anxiety?

The drug's primary mechanism is targeted to the nervous system of the gut to regulate motility. While adverse event reporting covers nervous system disorders, effects on general mood or anxiety are not noted as common side effects in the official product information.


Q: Is Alosetron safe to use with antacids?

While no specific warning exists for all general antacids, the FDA patient counseling information states that patients should discuss all over-the-counter medicines, including antacids, with their healthcare provider so that potential interactions or compounding effects can be assessed.


Q: Does Alosetron contain gluten or common allergens?

The brand name tablet is listed as containing lactose (anhydrous) as an inactive ingredient. Official labeling does not provide a comprehensive allergy statement or mention gluten. It is noted that patients may need to discuss all ingredients with their pharmacist or healthcare provider.


Q: Can Alosetron be taken with multivitamins?

The official guidance advises patients to tell their healthcare provider about all of their vitamins and supplements, including multivitamins, so that potential drug or additive effects can be assessed by a clinician.


Q: Does Alosetron change how other medicines are absorbed in the stomach?

Official data indicates Alosetron does not significantly interfere with the liver enzymes responsible for metabolizing most other drugs. However, because its mechanism slows gut motility, this change in movement could potentially affect the rate at which other oral medicines are absorbed. This possible effect is an area that requires assessment by a clinician.


Q: Can people with kidney problems use Alosetron?

Regulatory documents state that kidney impairment has no known effect on the minimal renal elimination of Alosetron. However, the effects of end-stage kidney disease and the resulting accumulation of the drug's metabolites have not been assessed in studies.

--TNQ-P6-End


Q: Does Alosetron interact with certain common herbal remedies?

Official patient guidance advises that patients inform their healthcare provider about all of their herbal products and supplements before starting or continuing the medication, as potential interactions must be identified by a clinician.


Q: Is Alosetron a controlled substance?

No, Alosetron is a prescription-only drug but is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or similar international bodies.


Q: Are there any specific conditions that make Alosetron less effective?

Alosetron is indicated only for women with severe diarrhea-predominant IBS (IBS-D) whose condition has not responded adequately to conventional therapies. If symptoms are not controlled after four weeks at the maximum approved dose, official instructions require the medicine to be discontinued, as it is considered ineffective for that patient.


Q: What happens when you stop taking Alosetron?

According to official patient counseling information, if treatment with Alosetron is stopped, your Irritable Bowel Syndrome symptoms may return to their previous severity within 1 or 2 weeks.


Q: Can Alosetron be taken by someone with lactose intolerance?

Official regulatory documents indicate that the tablets contain lactose (anhydrous) as an inactive ingredient. Individuals with known lactose intolerance should bring this to the attention of their healthcare provider or pharmacist when discussing this medicine.

How should Alosetron be stored and disposed of?

How to Store and Dispose of Alosetron

Alosetron tablets must be stored at a Controlled Room Temperature, specifically maintained between 20 C to 25 C (68 F to 77 F). Storage conditions strictly require the medicine to be protected from both light and moisture, and it must be kept from freezing. The tablets should remain in the original tight, light-resistant container as dispensed.

Child Safety and Disposal

It is mandatory that the medicine, which is supplied in child-resistant packaging, be stored strictly out of the reach of children. For disposal of unused or expired tablets, the official procedure is to utilize an available drug take-back program. If no take-back program is accessible, the tablets must be mixed with an unappealing substance, placed in a sealed bag, and discarded with household trash. Regulatory guidance advises against disposal by flushing down the toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Alosetron found in:

A-Z Index: